Shop By
Catalog No.
Product Name
Application
Product Information
Product Citation
-
influenza virus neuraminidase inhibitor
Oseltamivir acid (GS 4071), the active metabolite of Oseltamivir phosphate, is an orally bioavailable, potent and selective inhibitor of influenza virus neuraminidase (IC50=2 nM) with activity against both influenza A and B viruses. -
HCV Nucleoside Inhibitor
PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor.- Amitava Adhikary, .et al. , J Am Chem Soc., 2014, 136(44): 15646-15653 PMID: 25296262
-
HCV Nucleotide Inhibitor
PSI-7977 is a phosphoramidate prodrug of PSI-7851, a nucleoside analog that, when phosphorylated, inhibits the RNA-dependent RNA polymerase of hepatitis C virus (EC50 = 92 nM).- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
-
influenza virus neuraminidase (NA) inhibitor
Peramivir trihydrate (RWJ-270201 trihydrate;BCX-1812 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes. -
HCV NS5B polymerase inhibitor
Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication. -
NNRT inhibitor
Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. -
HIV Protease Inhibitor
Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. -
HCV NS3/4A protease inhibitor
Simeprevir is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). -
NS5B polymerase inhibitor
Tegobuvir (GS-9190 is a non-nucleoside NS5B polymerase inhibitor. -
viral RNA polymerase inhibitor
T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.
- Steven B Tillis, .et al. , Microorganisms, 2023, May 24;11(6):1371 PMID: 37374873
- Hyeon-Min Cha, .et al. , ACS Infect Dis, 2023, Apr 14;9(4):1033-1045 PMID: 36912867
- Satoko Yamaoka, .et al. , Antiviral Res, 2022, Apr;200:105291 PMID: 35296419
- Crystal A Mendoza, .et al. , Antiviral Res, 2021, Jan;185:104993 PMID: 33296695
- Liva Checkmahomed, .et al. , Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
- JE Comer, .et al. , Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
- Ma J, .et al. , Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
- Ji-Ae Kim, .et al. , Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
- Haejin Chun, .et al. , Polym Chem, 2018, 9: 2116-2123
- Baz M, .et al. , Viruses, 2018, Nov 3;10(11) PMID: 30400276
- Sehee Park, .et al. , PLoS One., 2014, 9(7): e101325 PMID: 24992479
-
HCV NS3/4A protease inhibitor
Vaniprevir is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. -
β-lactamase inhibitor
Sulbactam is a beta-lactamase inhibitor with an average IC50 of 0.8 μM.- Pholwat S, .et al. , PLoS One, 2019, May 10;14(5):e0216747 PMID: 31075137
-
HIV protease inhibitor
Darunavir Ethanolate (Prezista) is an HIV protease inhibitor. -
HCV NS3/4A protease inhibitor
Voxilaprevir (GS-9857) is a fluorinated macrocyclic hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms. GS-9857 improves coverage against commonly encountered NS3 resistance-associated variants (RAVs). -
NNRT inhibitor
MK-1439 is a non-nucleoside reverse transcriptase inhibitor -
DprE1 inhibitor
DprE1-IN-2 (compound 18) is a potent DprE1 inhibitor with an IC50 of 28 nM. DprE1-IN-2 has antituberculosis effect. -
squalene synthetase inhibitor
YM-53601 free base is a squalene synthetase inhibitor which suppresses lipogenic biosynthesis and lipid secretion in rodents. -
HIV protease inhibitor
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
NNRT inhibitor
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. -
Neuraminidase inhibitor
Laninamivir is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. -
HCV Polymerase Inhibitor
Setrobuvir (ANA-598) is a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase -
alpha-glucosidase I inhibitor
Celgosivir is an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. -
NS5A inhibitor
Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein- Miyayama Y, .et al. , Microbiol Immunol, 2019, Dec 19 PMID: 31854467
- Sayuri Nitta, .et al. , Scientific Reports, 2019, 9: 5722 PMID: 30952914
- Sayuri Nitta, .et al. , Sci Rep, 2016, 6: 34652 PMID: 27703205
-
HIV maturation inhibitor
GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. -
HSV inhibitor
ASP2151, is a herpes virus helicase-primase inhibitor. ASP2151 had significantly better anti-HSV activity against herpes simplex keratitis than valacyclovir and acyclovir after systemic or topical use. -
HIV-1 RT inhibitor
Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate. -
NNRT inhibitor
Delavirdine is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). -
helicase primase inhibitor
BAY 57-1293 is a potent helicase primase inhibitor. BAY 57-1293 inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. -
HCV NS5B polymerase inhibitor
BI 207127 was a non-nucleoside hepatitis C virus NS5B polymerase inhibitor for the treatment of hepatitis C -
CCR2/CCR5 inhibitor
Cenicriviroc is an experimental drug candidate for the treatment of HIV infection.Cenicriviroc is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell. -
IMPDH inhibitor
AVN-944 (also known as VX-944) serves as an effective oral inhibitor, specifically targeting and inhibiting IMPDH (inosine monophosphate dehydrogenase). This enzyme plays a crucial role as a rate-limiting factor in the synthesis of guanine nucleotides from scratch. Additionally, AVN-944 acts against the synthesis of RNA in arenaviruses, effectively preventing arenavirus infections. Demonstrating a wide spectrum of anti-cancer properties, AVN-944 is utilized in research related to multiple myeloma (MM) and acute myeloid leukemia (AML).
- Kevin Chiem, .et al. , Microbiol Spectr, 2023, Aug 17;11(4):e0474522 PMID: PMC10434227
- Desarey Morales Vasquez, .et al. , Viruses, 2020, Sep; 12(9): 1041 PMID: 32961956
- Park JG, .et al. , J Virol, 2020, Mar 17;94(7) PMID: 31941776
- Dunham EC, .et al. , Antiviral Res, 2018, Sep;157:140-150 PMID: 30031760
-
beta-lactamase inhibitor
Durlobactam, also known as ETX2514, is a beta-lactamase inhibitor drug candidate. -
HCV NS5A inhibitor
MK 8742, also known as Elbasvir, is a HCV NS5A inhibitor, which is an all-oral, interferon-free regimen for the treatment of HCV infection.
